GILD34 Stock Price and Chart — BMFBOVESPA:GILD34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Gilead Sciences Inc is heavily investing in antifungal drug R&D, including AmBisome. Redburn Atlantic set a price target of $123 for Gilead shares, indicating significant upside potential.

Jefferies has raised the price target for Gilead Sciences, Inc. to $105 from $95, with analysts reporting an average rating of outperform and price targets ranging from $69 to $123.

Analyze the impact Analyze the impact

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.